The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Nivolumab in resected and unresectable melanoma: Immune-related adverse events and association with survival outcomes.
 
Morganna L Freeman-Keller
No Relationships to Disclose
 
Jeffrey S. Weber
Stock and Other Ownership Interests - Altor BioScience; Celldex; Merck
Honoraria - Abbvie; Altor BioScience; Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; Daiichi Sankyo; Eisai; Genentech; GlaxoSmithKline; Ichor Medical Systems; Lion Biotechnologies; Merck; Merck; Pieris Pharmaceuticals; Roche
Consulting or Advisory Role - Abbvie; Altor BioScience; Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; Daiichi Sankyo; Eisai; Genentech; GlaxoSmithKline; Ichor Medical Systems; Lion Biotechnologies; Merck; Merck; Pieris Pharmaceuticals; Roche
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Merck (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; Daiichi Sankyo; Genentech; GlaxoSmithKline; Lion Biotechnologies; Merck; Merck; Pieris Pharmaceuticals; Roche